[클리니컬 히스토리] 종근당 CKD-703 환자 등록…데이터 축적 시작

Jongsundang's c-MET-targeted ADC therapy CKD-703 has initiated first patient enrollment in the US, entering the stage of accumulating real clinical data. As the company faces profitability pressure from increased reliance on licensed-in products, CKD-703 emerges as a critical asset demonstrating the company's proprietary drug development capabilities. Early safety data and patient enrollment velocity will be key determinants of the development timeline and future valuation multiples.